[go: up one dir, main page]

MX2016009751A - Agente mejorador del efecto de la rehabilitacion despues de una lesion nerviosa que comprende un derivado de eter de alquilo o una sal del mismo. - Google Patents

Agente mejorador del efecto de la rehabilitacion despues de una lesion nerviosa que comprende un derivado de eter de alquilo o una sal del mismo.

Info

Publication number
MX2016009751A
MX2016009751A MX2016009751A MX2016009751A MX2016009751A MX 2016009751 A MX2016009751 A MX 2016009751A MX 2016009751 A MX2016009751 A MX 2016009751A MX 2016009751 A MX2016009751 A MX 2016009751A MX 2016009751 A MX2016009751 A MX 2016009751A
Authority
MX
Mexico
Prior art keywords
salt
alkyl ether
enhancing agent
nerve injury
ether derivative
Prior art date
Application number
MX2016009751A
Other languages
English (en)
Inventor
Takahashi Takuya
Okuda Tomohiro
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of MX2016009751A publication Critical patent/MX2016009751A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • A61K9/5057Gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una composición medicinal caracterizada porque comprende un derivado de éter de alquilo representado por la fórmula general [1] (ver Fórmula) en donde R1 y R2 son los mismos o diferentes y representan un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C1-6 opcionalmente sustituido, un grupo arilo opcionalmente sustituido, etc.; R3 representa un grupo hidroxilo opcionalmente protegido; etc., y m y n son los mismos o diferentes, y representan un número entero desde 1 hasta 6] o una sal del mismo. La composición medicinal de acuerdo con la presente invención es útil como un agente mejorador del efecto de la rehabilitación después de una lesión nerviosa.
MX2016009751A 2014-01-31 2015-01-30 Agente mejorador del efecto de la rehabilitacion despues de una lesion nerviosa que comprende un derivado de eter de alquilo o una sal del mismo. MX2016009751A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014017587 2014-01-31
PCT/JP2015/052617 WO2015115582A1 (ja) 2014-01-31 2015-01-30 アルキルエーテル誘導体またはその塩を含有する神経損傷後のリハビリテーション効果促進剤

Publications (1)

Publication Number Publication Date
MX2016009751A true MX2016009751A (es) 2016-11-08

Family

ID=53757150

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009751A MX2016009751A (es) 2014-01-31 2015-01-30 Agente mejorador del efecto de la rehabilitacion despues de una lesion nerviosa que comprende un derivado de eter de alquilo o una sal del mismo.

Country Status (26)

Country Link
US (2) US10039744B2 (es)
EP (1) EP3100725B1 (es)
JP (3) JP5837726B1 (es)
KR (1) KR102346219B1 (es)
CN (1) CN106061478B (es)
AU (1) AU2015211753B2 (es)
BR (1) BR112016017747A2 (es)
CA (1) CA2938184C (es)
CY (1) CY1123154T1 (es)
DK (1) DK3100725T3 (es)
ES (1) ES2792950T3 (es)
HR (1) HRP20200796T1 (es)
HU (1) HUE050400T2 (es)
IL (1) IL246925B (es)
LT (1) LT3100725T (es)
MX (1) MX2016009751A (es)
MY (1) MY179290A (es)
PH (1) PH12016501507A1 (es)
PL (1) PL3100725T3 (es)
PT (1) PT3100725T (es)
RS (1) RS60462B1 (es)
RU (1) RU2680247C2 (es)
SG (2) SG11201606173TA (es)
SI (1) SI3100725T1 (es)
SM (1) SMT202000395T1 (es)
WO (1) WO2015115582A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3100725T (lt) * 2014-01-31 2020-08-10 Fujifilm Toyama Chemical Co., Ltd. Reabilitacijos poveikį po nervo pažeidimo sustiprinanti priemonė, apimanti alkileterio darinį arba jo druską
DK3395342T3 (da) * 2015-12-25 2020-10-12 Fujifilm Toyama Chemical Co Ltd Tablet omfattende 1-(3-(2-(1-benzothiophen-5-YL)ethoxy)propyl)azetidin-3-ol eller salt deraf
WO2018124282A1 (ja) * 2016-12-28 2018-07-05 富山化学工業株式会社 医薬組成物およびその製造方法
CN110167551B (zh) * 2016-12-28 2022-06-14 富士胶片富山化学株式会社 医药组合物
EP3563847B1 (en) * 2016-12-28 2023-09-20 FUJIFILM Toyama Chemical Co., Ltd. Pharmaceutical composition
EP3563843A4 (en) * 2016-12-28 2019-12-11 FUJIFILM Toyama Chemical Co., Ltd. TOPICAL COMPOSITION
EP3636262A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA
SG11201911519UA (en) 2017-06-02 2020-01-30 Fujifilm Toyama Chemical Co Ltd AGENT FOR REDUCING AMOUNT OF AMYLOID ß PROTEIN
WO2018221730A1 (ja) * 2017-06-02 2018-12-06 富山化学工業株式会社 脊髄小脳変性症予防または治療剤
RU2739199C1 (ru) * 2017-06-02 2020-12-21 ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. Лекарственное средство для предотврашения или лечения таупатии
CN116473962A (zh) 2017-06-02 2023-07-25 富士胶片富山化学株式会社 脑萎缩预防或治疗剂
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43676E1 (en) 2001-10-19 2012-09-18 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof
US7753054B2 (en) 2001-11-29 2010-07-13 Japan Science And Technology Agency Method of constructing spinal injury model monkey and utilization thereof
TR201816386T4 (tr) * 2002-06-14 2018-11-21 Toyama Chemical Co Ltd Beyin fonksiyonunu arttırmak için tıbbi bileşim.
US20060205709A1 (en) * 2003-04-17 2006-09-14 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
CA2799659C (en) 2005-03-28 2014-12-02 Toyama Chemical Co., Ltd. Process for production of 1-(3-(2-(1-benzothiophen-5-yl) ethoxy)propyl) azetidin-3-ol or salts thereof
RU2397169C2 (ru) * 2005-03-28 2010-08-20 Тояма Кемикал Ко., Лтд. Способ получения 1-(3-(2-(1-бензотиофен-5-ил)этокси) пропил)азетидин-3-ола или его солей
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
ZA200808728B (en) * 2006-04-26 2010-01-27 Toyama Chemical Co Ltd Neurogenesis inducer or neuropathy Therapeutic agent comprising alkyl ether derivative or salt thereof
LT3100725T (lt) * 2014-01-31 2020-08-10 Fujifilm Toyama Chemical Co., Ltd. Reabilitacijos poveikį po nervo pažeidimo sustiprinanti priemonė, apimanti alkileterio darinį arba jo druską

Also Published As

Publication number Publication date
JP2020073542A (ja) 2020-05-14
RU2680247C2 (ru) 2019-02-19
HRP20200796T1 (hr) 2020-08-07
IL246925B (en) 2019-10-31
EP3100725A4 (en) 2017-08-30
BR112016017747A2 (pt) 2017-08-08
CN106061478B (zh) 2019-04-30
US20170165227A1 (en) 2017-06-15
CA2938184C (en) 2021-11-23
JPWO2015115582A1 (ja) 2017-03-23
MY179290A (en) 2020-11-03
LT3100725T (lt) 2020-08-10
SG10201907035TA (en) 2019-09-27
IL246925A0 (en) 2016-09-29
RU2016135236A (ru) 2018-03-02
KR102346219B1 (ko) 2022-01-04
WO2015115582A1 (ja) 2015-08-06
PH12016501507A1 (en) 2017-02-06
CA2938184A1 (en) 2015-08-06
ES2792950T3 (es) 2020-11-12
SG11201606173TA (en) 2016-08-30
JP6825074B2 (ja) 2021-02-03
JP6642914B2 (ja) 2020-02-12
US10039744B2 (en) 2018-08-07
PT3100725T (pt) 2020-06-17
EP3100725B1 (en) 2020-05-06
SMT202000395T1 (it) 2020-09-10
US20180289668A1 (en) 2018-10-11
CN106061478A (zh) 2016-10-26
JP5837726B1 (ja) 2015-12-24
AU2015211753B2 (en) 2019-09-12
CY1123154T1 (el) 2021-10-29
AU2015211753A1 (en) 2016-08-11
SI3100725T1 (sl) 2020-08-31
US10471044B2 (en) 2019-11-12
HUE050400T2 (hu) 2020-12-28
JP2016074676A (ja) 2016-05-12
RU2016135236A3 (es) 2018-08-30
HK1226298A1 (en) 2017-09-29
EP3100725A1 (en) 2016-12-07
NZ722542A (en) 2021-07-30
RS60462B1 (sr) 2020-07-31
KR20160113281A (ko) 2016-09-28
PL3100725T3 (pl) 2020-11-16
DK3100725T3 (da) 2020-06-22

Similar Documents

Publication Publication Date Title
PH12016501507A1 (en) Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof
JOP20200225A1 (ar) مشتق كوينولين عالي النقاء وطريقة لإنتاجه
UY40612A (es) Piridinas sustituidas con heteroarilo y métodos de uso
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
JO3807B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
TN2015000245A1 (en) Heterocyclic compound
PH12022552034A1 (en) Pyridone derivative having tetrahydropyranyl methyl group
MX376283B (es) Compuestos de imidazopiridazina.
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
DOP2020000118A (es) Proceso para la preparación de derivados de quinolina
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
CL2017000103A1 (es) Derivados de bis(aril)catecol como herbicidas
CY1121626T1 (el) Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου
MY170262A (en) Dicarboxylic acid compound
NZ703217A (en) Novel cyclic depsipeptide derivatives and harmful organism control agents comprising the same
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
MX2019004294A (es) Derivados de fenilamina 4-sustituidos y su uso para proteger cultivos al combatir microorganismos fitopatogenicos indeseados.
JO3264B1 (ar) مركبات ازيتيدينيل أوكسي فينيل بيروليدين
MX386501B (es) Compuestos terapeuticos y sus metodos de uso
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2015010790A (es) Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc.
MX2017001320A (es) Amidas del acido arilcarboxilico biciclicas y su uso como herbicidas.
MX377963B (es) Composición acuosa.

Legal Events

Date Code Title Description
FG Grant or registration